ALX Oncology Holdings (ALXO) PE Ratio: History & Chart

ALX Oncology Holdings Inc.(ALXO)

Biotechnology · South San Francisco, CA

$1.16-0.05 (-4.55%)

Delayed quote: Oct 6, 2026, 11:45 AM EDT

About ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

South San Francisco, CA

48 employees

www.alxoncology.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jason Lettmann

View full financials

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
ALX Oncology Holdings Inc. (ALXO)	$155.42M	N/A	N/A	N/A	N/A
Cardiol Therapeutics Inc. (CRDL)vs ›	$154.46M	N/A	N/A	N/A	N/A
Minerva Neurosciences, Inc. (NERV)vs ›	$157.94M	N/A	4.03	4.03	14.59
Inogen, Inc. (INGN)vs ›	$159.02M	N/A	65.68	52.50	80.75
Codexis, Inc. (CDXS)vs ›	$152.20M	N/A	N/A	N/A	N/A
Anavex Life Sciences Corp. (AVXL)vs ›	$151.98M	N/A	N/A	N/A	N/A
Jyong Biotech Ltd. Ordinary Shares (MENS)vs ›	$159.28M	N/A	N/A	N/A	N/A
Acumen Pharmaceuticals, Inc. (ABOS)vs ›	$150.96M	N/A	N/A	N/A	N/A
NervGen Pharma Corp. Common stock (NGEN)vs ›	$148.36M	N/A	N/A	N/A	N/A
LifeMD, Inc. (LFMDP)vs ›	$147.97M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PE RATIO

TTM

ALX Oncology Holdings Inc. (ALXO)

$155.42M

N/A

Cardiol Therapeutics Inc. (CRDL)vs ›

$154.46M

N/A

Minerva Neurosciences, Inc. (NERV)vs ›

$157.94M

N/A

4.03

14.59

Inogen, Inc. (INGN)vs ›

$159.02M

N/A

65.68

52.50

80.75

Codexis, Inc. (CDXS)vs ›

$152.20M

N/A

Anavex Life Sciences Corp. (AVXL)vs ›

$151.98M

N/A

Jyong Biotech Ltd. Ordinary Shares (MENS)vs ›

$159.28M

N/A

Acumen Pharmaceuticals, Inc. (ABOS)vs ›

$150.96M

N/A

NervGen Pharma Corp. Common stock (NGEN)vs ›

$148.36M

N/A

LifeMD, Inc. (LFMDP)vs ›

$147.97M

N/A

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

PE Ratio: N/A

ALXO PE Ratio Metrics

ALXO Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics